Study assessing COVID-19 vaccine reactogenicity - A cohort event monitoring study in the Netherlands using patient reported outcomes
Latest Information Update: 31 Jan 2022
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 31 Jan 2022 New trial record
- 17 Jan 2022 Results published in the Vaccine